ABCL (AbCellera Biologics) Other Operating Expense: $9.60 Mil (TTM As of Mar. 2026)


ABCL AbCellera Biologics Inc ABCL
56 GF Score
Price $8.11
GF Value $5.50
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Other Operating Expense?

AbCellera Biologics ABCL +6.78% 56 Other Operating Expense is $9.60 Mil as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 56/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 5 warning signs investors should review.

AbCellera Biologics's Other Operating Expense for the three months ended in Mar. 2026 was $2.50 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $9.60 Mil.

AbCellera Biologics's quarterly Other Operating Expense increased from Sep. 2025 ($2.52 Mil) to Dec. 2025 ($2.81 Mil) but then declined from Dec. 2025 ($2.81 Mil) to Mar. 2026 ($2.50 Mil).

AbCellera Biologics's annual Other Operating Expense increased from Dec. 2023 ($10.24 Mil) to Dec. 2024 ($77.23 Mil) but then declined from Dec. 2024 ($77.23 Mil) to Dec. 2025 ($8.28 Mil).

AbCellera Biologics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Other Operating Expense Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial -3.03 17.29 10.24 77.23 8.28

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.78 2.52 2.81 2.50
ABCL
56GF Score
AbCellera Biologics Inc ABCL
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $9.60 Mil mean?
AbCellera Biologics (ABCL) has a Other Operating Expense of $9.60 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on AbCellera Biologics and its competitors.
Is AbCellera Biologics' Other Operating Expense too high?
AbCellera Biologics' current Other Operating Expense is $9.60 Mil. Overall, AbCellera Biologics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Other Operating Expense compare to AGIO and KOD?
AbCellera Biologics' Other Operating Expense of $9.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Other Operating Expense is $9.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $8.11 — trading 47.5% above its estimated fair value. The current Other Operating Expense is $9.60 Mil. AbCellera Biologics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Other Operating Expense is $9.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $8.11 is trading 47.5% above its estimated GF Value™ of $5.50. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Other Operating Expense: $9.60 Mil
  • GF Value™: $5.50 vs. price of $8.11 (47.5% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
56GF Score

Get the complete analysis for ABCL

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.11
Price
$5.50
GF Value